BINGBING DAI to Tumor Burden
This is a "connection" page, showing publications BINGBING DAI has written about Tumor Burden.
Connection Strength
0.139
-
Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Cell Death Dis. 2021 07 10; 12(7):693.
Score: 0.124
-
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010 Nov 29; 5(11):e14124.
Score: 0.015